| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.793 | 0.004 | 0.793 | Vasodilator, coronary | 0.661 0.005 DBMET01141 | ||
| 0.685 | 0.004 | 0.685 | Diuretic | 0.649 0.004 DBMET01141 0.157 0.071 DBMET02776 | ||
| 0.677 | 0.008 | 0.718 | Vasodilator, peripheral | 0.26 0.12 DBMET02775 0.718 0.005 DBMET01141 0.287 0.103 DBMET02776 | DBMET01141 | |
| 0.596 | 0.013 | 0.596 | Spasmolytic | 0.436 0.033 DBMET01141 | ||
| 0.585 | 0.018 | 0.585 | Antithrombotic | 0.274 0.107 DBMET02775 0.563 0.02 DBMET01141 0.272 0.109 DBMET02776 | ||
| 0.489 | 0.002 | 0.561 | Angiotensin-converting enzyme inhibitor | 0.062 0.028 DBMET02775 0.561 0.002 DBMET01141 0.07 0.02 DBMET02776 | DBMET01141 | |
| 0.49 | 0.013 | 0.49 | Vasodilator | 0.222 0.088 DBMET02775 0.469 0.014 DBMET01141 | ||
| 0.454 | 0.011 | 0.454 | Thiol protease inhibitor | 0.403 0.013 DBMET01141 | ||
| 0.461 | 0.047 | 0.461 | 5 Hydroxytryptamine release inhibitor | 0.312 0.152 DBMET02775 0.323 0.14 DBMET01141 0.259 0.216 DBMET02776 | ||
| 0.402 | 0.005 | 0.425 | Neurotrophic factor | 0.345 0.006 DBMET02775 0.425 0.004 DBMET01141 0.366 0.005 DBMET02776 | DBMET01141 | |
| 0.436 | 0.04 | 0.436 | Immunostimulant | 0.426 0.042 DBMET01141 | ||
| 0.404 | 0.011 | 0.459 | Thrombolytic | 0.167 0.069 DBMET02775 0.459 0.007 DBMET01141 0.262 0.031 DBMET02776 | DBMET01141 | |
| 0.407 | 0.021 | 0.426 | Psychostimulant | 0.426 0.019 DBMET01141 | DBMET01141 | |
| 0.402 | 0.028 | 0.402 | Cardiotonic | 0.221 0.102 DBMET02775 0.391 0.03 DBMET01141 0.203 0.116 DBMET02776 | ||
| 0.432 | 0.059 | 0.432 | Histamine release inhibitor | 0.343 0.103 DBMET01141 | ||
| 0.385 | 0.03 | 0.427 | Platelet antagonist | 0.319 0.047 DBMET02775 0.427 0.023 DBMET01141 0.366 0.034 DBMET02776 | DBMET01141 | |
| 0.36 | 0.026 | 0.398 | Interleukin agonist | 0.277 0.061 DBMET02775 0.398 0.019 DBMET01141 0.312 0.042 DBMET02776 | DBMET01141 | |
| 0.356 | 0.032 | 0.36 | Insulysin inhibitor | 0.187 0.179 DBMET02775 0.36 0.031 DBMET01141 0.245 0.101 DBMET02776 | DBMET01141 | |
| 0.335 | 0.023 | 0.381 | Anticoagulant | 0.121 0.11 DBMET02775 0.381 0.018 DBMET01141 0.148 0.082 DBMET02776 | DBMET01141 | |
| 0.316 | 0.013 | 0.322 | Insulin sensitizer | 0.322 0.012 DBMET01141 | DBMET01141 | |
| 0.299 | 0.008 | 0.358 | Aminopeptidase B inhibitor | 0.358 0.005 DBMET01141 | DBMET01141 | |
| 0.301 | 0.032 | 0.326 | Tyrosine 3 hydroxylase inhibitor | 0.317 0.026 DBMET02775 0.326 0.023 DBMET01141 0.32 0.025 DBMET02776 | DBMET01141 | |
| 0.373 | 0.107 | 0.402 | Cyclophilin D inhibitor | 0.402 0.09 DBMET01141 | DBMET01141 | |
| 0.275 | 0.017 | 0.305 | Neurotensin receptor agonist | 0.305 0.014 DBMET01141 0.145 0.115 DBMET02776 | DBMET01141 | |
| 0.299 | 0.049 | 0.323 | Angiogenesis stimulant | 0.162 0.115 DBMET02775 0.323 0.041 DBMET01141 0.21 0.089 DBMET02776 | DBMET01141 | |
| 0.301 | 0.052 | 0.301 | Hypoglycemic | 0.268 0.067 DBMET01141 | ||
| 0.358 | 0.111 | 0.358 | Calcium channel L-type activator | 0.288 0.168 DBMET02775 0.284 0.171 DBMET01141 0.253 0.202 DBMET02776 | ||
| 0.309 | 0.067 | 0.438 | Interleukin 2 agonist | 0.383 0.033 DBMET02775 0.38 0.034 DBMET01141 0.438 0.018 DBMET02776 | DBMET02776 | |
| 0.304 | 0.089 | 0.304 | Cholesterol antagonist | 0.223 0.145 DBMET01141 | ||
| 0.203 | 0.003 | 0.219 | Prolyl endopeptidase inhibitor | 0.219 0.003 DBMET01141 | DBMET01141 | |
| 0.23 | 0.048 | 0.23 | P-glycoprotein inhibitor | 0.227 0.05 DBMET02775 0.205 0.061 DBMET01141 0.22 0.053 DBMET02776 | ||
| 0.201 | 0.024 | 0.252 | Cell adhesion inhibitor | 0.105 0.08 DBMET02775 0.252 0.015 DBMET01141 0.159 0.041 DBMET02776 | DBMET01141 | |
| 0.278 | 0.108 | 0.278 | Transcription factor NF kappa B inhibitor | 0.245 0.131 DBMET01141 | ||
| 0.254 | 0.087 | 0.455 | 5 Hydroxytryptamine release stimulant | 0.455 0.035 DBMET02775 0.181 0.14 DBMET01141 0.29 0.073 DBMET02776 | DBMET02775 | |
| 0.245 | 0.085 | 0.297 | Gastrin inhibitor | 0.297 0.035 DBMET01141 | DBMET01141 | |
| 0.28 | 0.128 | 0.28 | Immunosuppressant | 0.249 0.148 DBMET02775 0.276 0.131 DBMET01141 0.274 0.132 DBMET02776 | ||
| 0.151 | 0.003 | 0.279 | Angiotensin-converting enzyme 2 inhibitor | 0.279 0.002 DBMET01141 | DBMET01141 | |
| 0.174 | 0.034 | 0.174 | Proteasome inhibitor | 0.155 0.044 DBMET01141 | ||
| 0.171 | 0.033 | 0.235 | Cathepsin H inhibitor | 0.235 0.015 DBMET01141 | DBMET01141 | |
| 0.226 | 0.089 | 0.226 | Calpain inhibitor | 0.183 0.131 DBMET01141 | ||
| 0.25 | 0.115 | 0.333 | Immunomodulator | 0.316 0.074 DBMET02775 0.272 0.099 DBMET01141 0.333 0.066 DBMET02776 | DBMET02776 | |
| 0.137 | 0.006 | 0.137 | Leukocyte elastase inhibitor | 0.088 0.011 DBMET01141 | ||
| 0.149 | 0.02 | 0.191 | Opioid delta receptor antagonist | 0.057 0.049 DBMET02775 0.191 0.012 DBMET01141 0.095 0.031 DBMET02776 | DBMET01141 | |
| 0.19 | 0.063 | 0.273 | Growth hormone agonist | 0.273 0.038 DBMET01141 | DBMET01141 | |
| 0.198 | 0.072 | 0.216 | Platelet adhesion inhibitor | 0.216 0.063 DBMET01141 | DBMET01141 | |
| 0.145 | 0.024 | 0.192 | Folate antagonist | 0.192 0.011 DBMET01141 | DBMET01141 | |
| 0.143 | 0.028 | 0.182 | Opioid antagonist | 0.087 0.06 DBMET02775 0.182 0.018 DBMET01141 0.116 0.038 DBMET02776 | DBMET01141 | |
| 0.131 | 0.02 | 0.169 | Cell adhesion molecule inhibitor | 0.169 0.012 DBMET01141 | DBMET01141 | |
| 0.162 | 0.055 | 0.183 | Hemostatic | 0.183 0.04 DBMET01141 | DBMET01141 | |
| 0.117 | 0.013 | 0.117 | Elastase 1 inhibitor | 0.101 0.019 DBMET01141 | ||
| 0.117 | 0.02 | 0.2 | Aminopeptidase I inhibitor | 0.2 0.007 DBMET01141 | DBMET01141 | |
| 0.123 | 0.028 | 0.181 | Metalloproteinase-2 inhibitor | 0.181 0.013 DBMET01141 | DBMET01141 | |
| 0.158 | 0.063 | 0.167 | Protein kinase stimulant | 0.167 0.057 DBMET01141 | DBMET01141 | |
| 0.237 | 0.143 | 0.295 | Sodium/bile acid cotransporter inhibitor | 0.295 0.084 DBMET01141 0.252 0.126 DBMET02776 | DBMET01141 | |
| 0.117 | 0.024 | 0.137 | Analgesic, opioid | 0.067 0.066 DBMET02775 0.137 0.018 DBMET01141 0.078 0.05 DBMET02776 | DBMET01141 | |
| 0.118 | 0.025 | 0.156 | Opioid mu receptor antagonist | 0.062 0.052 DBMET02775 0.156 0.016 DBMET01141 0.091 0.035 DBMET02776 | DBMET01141 | |
| 0.109 | 0.018 | 0.14 | Glucagon-like peptide 1 agonist | 0.14 0.01 DBMET01141 0.06 0.048 DBMET02776 | DBMET01141 | |
| 0.13 | 0.04 | 0.142 | Falcipain inhibitor | 0.142 0.035 DBMET01141 | DBMET01141 | |
| 0.126 | 0.039 | 0.137 | Falcipain 2 inhibitor | 0.137 0.034 DBMET01141 | DBMET01141 | |
| 0.108 | 0.023 | 0.146 | Matrix metalloproteinase inhibitor | 0.146 0.014 DBMET01141 | DBMET01141 | |
| 0.2 | 0.118 | 0.308 | Superoxide dismutase inhibitor | 0.308 0.048 DBMET01141 | DBMET01141 | |
| 0.124 | 0.042 | 0.124 | Acetylcholine release stimulant | |||
| 0.123 | 0.045 | 0.123 | Protease inhibitor | 0.121 0.047 DBMET01141 | ||
| 0.142 | 0.066 | 0.152 | Bone formation stimulant | 0.152 0.057 DBMET01141 | DBMET01141 | |
| 0.115 | 0.039 | 0.124 | Interleukin 1 beta converting enzyme inhibitor | 0.124 0.032 DBMET01141 | DBMET01141 | |
| 0.092 | 0.016 | 0.135 | Matrix metalloproteinase (membrane-type) inhibitor | 0.135 0.01 DBMET01141 | DBMET01141 | |
| 0.149 | 0.075 | 0.167 | Insulin secretagoues | 0.167 0.058 DBMET01141 | DBMET01141 | |
| 0.105 | 0.033 | 0.105 | Chymotrypsin inhibitor | 0.071 0.069 DBMET02775 0.102 0.035 DBMET01141 | ||
| 0.084 | 0.015 | 0.106 | Metalloproteinase-3 inhibitor | 0.106 0.009 DBMET01141 | DBMET01141 | |
| 0.222 | 0.154 | 0.233 | Apoptosis antagonist | 0.233 0.144 DBMET01141 | DBMET01141 | |
| 0.089 | 0.022 | 0.089 | Beta adrenoreceptor antagonist | 0.068 0.042 DBMET01141 | ||
| 0.086 | 0.023 | 0.086 | Protease 3C (Human rhinovirus) inhibitor | |||
| 0.098 | 0.034 | 0.113 | Cathepsin G inhibitor | 0.113 0.029 DBMET01141 0.071 0.053 DBMET02776 | DBMET01141 | |
| 0.118 | 0.055 | 0.168 | Falcipain 3 inhibitor | 0.168 0.029 DBMET01141 | DBMET01141 | |
| 0.161 | 0.098 | 0.161 | Hepatoprotectant | 0.148 0.112 DBMET01141 | ||
| 0.067 | 0.005 | 0.108 | Neutral endopeptidase inhibitor | 0.108 0.004 DBMET01141 | DBMET01141 | |
| 0.103 | 0.045 | 0.398 | NMDA receptor antagonist | 0.146 0.026 DBMET02775 0.171 0.019 DBMET01141 0.398 0.005 DBMET02776 | DBMET02776 | |
| 0.078 | 0.024 | 0.085 | Cathepsin E inhibitor | 0.085 0.019 DBMET01141 | DBMET01141 | |
| 0.073 | 0.02 | 0.073 | Elastase inhibitor | 0.07 0.022 DBMET01141 | ||
| 0.061 | 0.008 | 0.072 | Angiotensin AT2 receptor antagonist | 0.072 0.006 DBMET01141 | DBMET01141 | |
| 0.057 | 0.005 | 0.066 | Angiotensin II receptor antagonist | 0.066 0.004 DBMET01141 | DBMET01141 | |
| 0.087 | 0.035 | 0.091 | Thrombin inhibitor | 0.091 0.031 DBMET01141 | DBMET01141 | |
| 0.094 | 0.044 | 0.11 | Factor XII inhibitor | 0.097 0.04 DBMET02775 0.11 0.03 DBMET01141 0.102 0.036 DBMET02776 | DBMET01141 | |
| 0.056 | 0.006 | 0.073 | Glutamate (mGluR8) antagonist | 0.073 0.004 DBMET01141 | DBMET01141 | |
| 0.065 | 0.017 | 0.089 | HCV NS3/NS4A protease inhibitor | 0.089 0.008 DBMET01141 0.045 0.043 DBMET02776 | DBMET01141 | |
| 0.075 | 0.027 | 0.075 | Nitric oxide donor | 0.058 0.051 DBMET01141 | ||
| 0.062 | 0.015 | 0.167 | Kainate receptor antagonist | 0.167 0.004 DBMET01141 | DBMET01141 | |
| 0.067 | 0.02 | 0.109 | Dipeptidyl peptidase inhibitor | 0.109 0.008 DBMET01141 | DBMET01141 | |
| 0.092 | 0.046 | 0.105 | Hematopoietic | 0.082 0.068 DBMET02775 0.105 0.031 DBMET01141 0.092 0.046 DBMET02776 | DBMET01141 | |
| 0.055 | 0.012 | 0.086 | Arginase inhibitor | 0.086 0.005 DBMET01141 | DBMET01141 | |
| 0.054 | 0.012 | 0.058 | Baculoviral IAP repeat-containing protein inhibitor | 0.058 0.007 DBMET01141 | DBMET01141 | |
| 0.054 | 0.011 | 0.06 | Phenylethanolamine N methyltransferase inhibitor | 0.06 0.008 DBMET01141 0.038 0.035 DBMET02776 | DBMET01141 | |
| 0.135 | 0.093 | 0.135 | Phospholipase A2 inhibitor | |||
| 0.058 | 0.017 | 0.063 | Leukotriene A4 hydrolase inhibitor | 0.063 0.014 DBMET01141 | DBMET01141 | |
| 0.088 | 0.048 | 0.112 | Opioid kappa receptor antagonist | 0.093 0.042 DBMET02775 0.104 0.031 DBMET01141 0.112 0.027 DBMET02776 | DBMET02776 | |
| 0.112 | 0.072 | 0.12 | Caspase 3 inhibitor | 0.12 0.059 DBMET01141 | DBMET01141 | |
| 0.074 | 0.036 | 0.131 | Neutrophil collagenase inhibitor | 0.131 0.015 DBMET01141 | DBMET01141 | |
| 0.07 | 0.033 | 0.077 | Trypsin inhibitor | 0.077 0.028 DBMET01141 | DBMET01141 | |
| 0.059 | 0.024 | 0.1 | Neurotensin receptor antagonist | 0.1 0.014 DBMET01141 | DBMET01141 | |
| 0.066 | 0.031 | 0.066 | Human rhinovirus A protease inhibitor | 0.06 0.034 DBMET01141 | ||
| 0.067 | 0.032 | 0.067 | Cathepsin L inhibitor | 0.064 0.035 DBMET01141 | ||
| 0.105 | 0.071 | 0.105 | Mucolytic | 0.096 0.084 DBMET01141 | ||
| 0.101 | 0.068 | 0.103 | Factor V inhibitor | 0.103 0.063 DBMET01141 | DBMET01141 | |
| 0.046 | 0.014 | 0.046 | Integrin alpha2 antagonist | 0.045 0.015 DBMET01141 | ||
| 0.059 | 0.028 | 0.098 | GP IIb/IIIa receptor antagonist | 0.098 0.018 DBMET01141 0.05 0.033 DBMET02776 | DBMET01141 | |
| 0.13 | 0.099 | 0.13 | Neuropeptide Y1 antagonist | |||
| 0.1 | 0.069 | 0.1 | Expectorant | 0.093 0.078 DBMET01141 | ||
| 0.066 | 0.035 | 0.079 | Aminopeptidase microsomal inhibitor | 0.079 0.026 DBMET01141 | DBMET01141 | |
| 0.05 | 0.02 | 0.082 | Dipeptidyl peptidase IV inhibitor | 0.082 0.007 DBMET01141 | DBMET01141 | |
| 0.081 | 0.051 | 0.093 | Somatostatin 1 agonist | 0.073 0.06 DBMET02775 0.093 0.039 DBMET01141 0.089 0.042 DBMET02776 | DBMET01141 | |
| 0.047 | 0.018 | 0.061 | Calcitonin receptor agonist | 0.061 0.014 DBMET01141 | DBMET01141 | |
| 0.037 | 0.009 | 0.087 | LFA antagonist | 0.087 0.004 DBMET01141 | DBMET01141 | |
| 0.054 | 0.026 | 0.071 | Opioid mu receptor agonist | 0.071 0.02 DBMET01141 0.047 0.031 DBMET02776 | DBMET01141 | |
| 0.058 | 0.031 | 0.126 | NMDA 2A receptor antagonist | 0.126 0.009 DBMET01141 | DBMET01141 | |
| 0.065 | 0.038 | 0.069 | Caspase 9 inhibitor | 0.069 0.033 DBMET01141 | DBMET01141 | |
| 0.047 | 0.022 | 0.053 | Angiotensin AT1 receptor antagonist | 0.053 0.014 DBMET01141 | DBMET01141 | |
| 0.118 | 0.094 | 0.118 | Vanilloid 1 agonist | |||
| 0.039 | 0.016 | 0.055 | Caspase 2 inhibitor | 0.055 0.01 DBMET01141 | DBMET01141 | |
| 0.054 | 0.035 | 0.068 | Opioid agonist | 0.068 0.024 DBMET01141 | DBMET01141 | |
| 0.062 | 0.043 | 0.097 | NMDA 2C receptor antagonist | 0.097 0.017 DBMET01141 | DBMET01141 | |
| 0.032 | 0.015 | 0.087 | Lysine carboxypeptidase inhibitor | 0.087 0.004 DBMET01141 | DBMET01141 | |
| 0.056 | 0.039 | 0.058 | Cathepsin B inhibitor | 0.058 0.037 DBMET01141 | DBMET01141 | |
| 0.053 | 0.037 | 0.083 | Matrix metalloproteinase 1 inhibitor | 0.083 0.02 DBMET01141 | DBMET01141 | |
| 0.124 | 0.109 | 0.145 | Protein-tyrosine phosphatase inhibitor | 0.145 0.084 DBMET01141 | DBMET01141 | |
| 0.099 | 0.084 | 0.099 | Anesthetic local | |||
| 0.059 | 0.044 | 0.065 | Bcl-xL inhibitor | 0.06 0.04 DBMET01141 0.065 0.028 DBMET02776 | DBMET02776 | |
| 0.047 | 0.033 | 0.057 | Plasmin inhibitor | 0.057 0.029 DBMET01141 | DBMET01141 | |
| 0.043 | 0.03 | 0.052 | Glutamate (mGluR4) antagonist | 0.052 0.019 DBMET01141 | DBMET01141 | |
| 0.022 | 0.01 | 0.023 | Baculoviral IAP repeat-containing protein 3 inhibitor | 0.023 0.008 DBMET01141 | DBMET01141 | |
| 0.222 | 0.211 | 0.356 | Analgesic | 0.356 0.105 DBMET02775 0.253 0.18 DBMET01141 0.298 0.143 DBMET02776 | DBMET02775 | |
| 0.044 | 0.034 | 0.055 | Farnesyltransferase inhibitor | 0.055 0.023 DBMET01141 | DBMET01141 | |
| 0.045 | 0.036 | 0.057 | Aminopeptidase N inhibitor | 0.057 0.026 DBMET01141 | DBMET01141 | |
| 0.048 | 0.039 | 0.068 | CD45 antagonist | 0.068 0.016 DBMET01141 | DBMET01141 | |
| 0.037 | 0.029 | 0.045 | Integrin alpha1beta1 antagonist | 0.045 0.012 DBMET01141 | DBMET01141 | |
| 0.018 | 0.01 | 0.043 | Integrin alpha4beta1 antagonist | 0.043 0.005 DBMET01141 | DBMET01141 | |
| 0.039 | 0.031 | 0.141 | Integrin antagonist | 0.141 0.011 DBMET01141 | DBMET01141 | |
| 0.029 | 0.022 | 0.029 | Trypsin II inhibitor | |||
| 0.027 | 0.02 | 0.038 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.038 0.008 DBMET01141 | DBMET01141 | |
| 0.056 | 0.049 | 0.056 | Neuraminidase inhibitor | 0.055 0.05 DBMET01141 | ||
| 0.047 | 0.04 | 0.055 | Collagenase inhibitor | 0.055 0.022 DBMET01141 | DBMET01141 | |
| 0.06 | 0.053 | 0.079 | Prolactin release inhibitor | 0.072 0.02 DBMET02775 0.068 0.026 DBMET01141 0.079 0.012 DBMET02776 | DBMET02776 | |
| 0.039 | 0.032 | 0.048 | Melanocortin 4 antagonist | 0.048 0.025 DBMET01141 | DBMET01141 | |
| 0.138 | 0.132 | 0.166 | Phospholipase C inhibitor | 0.166 0.078 DBMET01141 | DBMET01141 | |
| 0.15 | 0.144 | 0.15 | Free radical scavenger | |||
| 0.063 | 0.057 | 0.072 | Glutamate (mGluR6) antagonist | 0.072 0.036 DBMET01141 | DBMET01141 | |
| 0.034 | 0.029 | 0.04 | Tryptophan 5 hydroxylase inhibitor | 0.04 0.015 DBMET01141 | DBMET01141 | |
| 0.236 | 0.23 | 0.236 | Apoptosis agonist | |||
| 0.035 | 0.03 | 0.043 | Cholecystokinin B agonist | 0.043 0.02 DBMET01141 | DBMET01141 | |
| 0.039 | 0.034 | 0.05 | Sphingosine 1-phosphate receptor 1 agonist | 0.05 0.02 DBMET01141 | DBMET01141 | |
| 0.033 | 0.028 | 0.038 | Opioid delta receptor agonist | 0.038 0.021 DBMET01141 | DBMET01141 | |
| 0.051 | 0.047 | 0.065 | Plasminogen activator inhibitor | 0.065 0.036 DBMET01141 | DBMET01141 | |
| 0.025 | 0.021 | 0.025 | Integrin alpha2beta1 antagonist | |||
| 0.02 | 0.017 | 0.021 | Neuraminidase (Influenza B) inhibitor | 0.021 0.015 DBMET01141 | DBMET01141 | |
| 0.014 | 0.011 | 0.034 | Glucagon agonist | 0.034 0.005 DBMET01141 | DBMET01141 | |
| 0.042 | 0.04 | 0.049 | Melanocortin antagonist | 0.042 0.04 DBMET02775 0.049 0.031 DBMET01141 0.045 0.035 DBMET02776 | DBMET01141 | |
| 0.012 | 0.009 | 0.032 | Integrin beta2 antagonist | 0.032 0.004 DBMET01141 | DBMET01141 | |
| 0.025 | 0.023 | 0.032 | NMDA 2D receptor antagonist | 0.032 0.014 DBMET01141 | DBMET01141 | |
| 0.021 | 0.019 | 0.101 | Aminopeptidase P inhibitor | 0.062 0.003 DBMET02775 0.023 0.016 DBMET01141 0.101 0.002 DBMET02776 | DBMET02776 | |
| 0.101 | 0.1 | 0.161 | Alpha-N-acetylglucosaminidase inhibitor | 0.161 0.049 DBMET01141 | DBMET01141 | |
| 0.031 | 0.03 | 0.096 | Kainate receptor 2 antagonist | 0.096 0.005 DBMET01141 | DBMET01141 | |
| 0.174 | 0.173 | 0.174 | Transcription factor STAT3 inhibitor | |||
| 0.014 | 0.014 | 0.016 | Dipeptidyl peptidase VIII inhibitor | 0.016 0.01 DBMET01141 | DBMET01141 | |
| 0.107 | 0.108 | 0.141 | Histone deacetylase SIRT1 inhibitor | 0.141 0.07 DBMET01141 | DBMET01141 | |
| 0.024 | 0.026 | 0.097 | AMPA 3 receptor antagonist | 0.097 0.004 DBMET01141 | DBMET01141 | |
| 0.016 | 0.019 | 0.019 | Tryptophan hydroxylase 1 inhibitor | 0.019 0.008 DBMET01141 | DBMET01141 | |
| 0.042 | 0.047 | 0.072 | Ribonucleoside-diphosphate reductase inhibitor | 0.072 0.028 DBMET01141 | DBMET01141 | |
| 0.023 | 0.028 | 0.028 | Bradykinin B2 receptor agonist | 0.028 0.02 DBMET01141 | DBMET01141 | |
| 0.03 | 0.036 | 0.038 | Melanocortin 1 antagonist | 0.038 0.026 DBMET01141 | DBMET01141 | |
| 0.022 | 0.028 | 0.04 | Bradykinin B2 receptor antagonist | 0.04 0.016 DBMET01141 | DBMET01141 | |
| 0.025 | 0.032 | 0.033 | Trypsin I inhibitor | 0.033 0.023 DBMET01141 | DBMET01141 | |
| 0.012 | 0.019 | 0.014 | Dipeptidyl peptidase IX inhibitor | 0.014 0.013 DBMET01141 | DBMET01141 | |
| 0.035 | 0.043 | 0.053 | Endothelin-converting enzyme inhibitor | 0.053 0.028 DBMET01141 | DBMET01141 | |
| 0.063 | 0.071 | 0.101 | Metalloproteinase-9 inhibitor | 0.101 0.032 DBMET01141 | DBMET01141 | |
| 0.038 | 0.047 | 0.046 | Glutamate (mGluR group III) antagonist | 0.046 0.026 DBMET01141 | DBMET01141 | |
| 0.023 | 0.032 | 0.026 | HCV NS5A inhibitor | 0.026 0.023 DBMET01141 | DBMET01141 | |
| 0.042 | 0.051 | 0.049 | Bombesin 2 receptor antagonist | 0.049 0.035 DBMET01141 | DBMET01141 | |
| 0.012 | 0.021 | 0.03 | Aminopeptidase A inhibitor | 0.03 0.006 DBMET01141 | DBMET01141 | |
| 0.041 | 0.05 | 0.072 | Ribonucleotide reductase inhibitor | 0.072 0.03 DBMET01141 | DBMET01141 | |
| 0.047 | 0.056 | 0.068 | CXC chemokine 4 receptor antagonist | 0.068 0.037 DBMET01141 | DBMET01141 | |
| 0.016 | 0.026 | 0.02 | Caspase 8 inhibitor | 0.02 0.013 DBMET01141 | DBMET01141 | |
| 0.085 | 0.096 | 0.102 | Protein-tyrosine phosphatase 1B inhibitor | 0.102 0.076 DBMET01141 | DBMET01141 | |
| 0.016 | 0.027 | 0.062 | Integrin alpha4 antagonist | 0.062 0.009 DBMET01141 | DBMET01141 | |
| 0.021 | 0.032 | 0.051 | AMPA 2 receptor antagonist | 0.051 0.011 DBMET01141 | DBMET01141 | |
| 0.03 | 0.041 | 0.035 | HCV polyprotein inhibitor | 0.035 0.02 DBMET01141 | DBMET01141 | |
| 0.009 | 0.022 | 0.014 | Integrin alphaLbeta2 antagonist | 0.014 0.008 DBMET01141 | DBMET01141 | |
| 0.033 | 0.046 | 0.04 | Opioid kappa receptor agonist | 0.04 0.035 DBMET01141 | DBMET01141 | |
| 0.025 | 0.04 | 0.049 | Cholecystokinin antagonist | 0.049 0.025 DBMET01141 | DBMET01141 | |
| 0.032 | 0.046 | 0.045 | Integrin alpha5beta1 antagonist | 0.045 0.022 DBMET01141 | DBMET01141 | |
| 0.016 | 0.034 | 0.064 | AMPA 1 receptor antagonist | 0.064 0.009 DBMET01141 | DBMET01141 | |
| 0.026 | 0.046 | 0.057 | Complement C3a chemotactic receptor antagonist | 0.057 0.023 DBMET01141 | DBMET01141 | |
| 0.033 | 0.053 | 0.044 | Sphingosine 1-phosphate receptor agonist | 0.044 0.031 DBMET01141 | DBMET01141 | |
| 0.074 | 0.095 | 0.179 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.179 0.02 DBMET01141 | DBMET01141 | |
| 0.011 | 0.032 | 0.016 | Kainate receptor 3 antagonist | 0.016 0.013 DBMET01141 | DBMET01141 | |
| 0.009 | 0.031 | 0.062 | Kainate receptor 1 antagonist | 0.062 0.005 DBMET01141 | DBMET01141 | |
| 0.193 | 0.217 | 0.349 | Antiobesity | 0.235 0.172 DBMET02775 0.241 0.165 DBMET01141 0.349 0.088 DBMET02776 | DBMET02776 | |
| 0.048 | 0.073 | 0.101 | NMDA receptor agonist | 0.101 0.019 DBMET01141 0.058 0.051 DBMET02776 | DBMET01141 | |
| 0.024 | 0.049 | 0.061 | NMDA receptor subunit 3A antagonist | 0.061 0.016 DBMET01141 | DBMET01141 | |
| 0.024 | 0.051 | 0.036 | Bradykinin antagonist | 0.036 0.026 DBMET01141 | DBMET01141 | |
| 0.005 | 0.034 | 0.012 | Angiotensin AT1B receptor antagonist | 0.012 0.011 DBMET01141 | DBMET01141 | |
| 0.009 | 0.039 | 0.019 | Integrin alpha4beta7 antagonist | 0.019 0.016 DBMET01141 | DBMET01141 | |
| 0.021 | 0.069 | 0.033 | Dipeptidyl peptidase II inhibitor | 0.033 0.022 DBMET01141 | DBMET01141 | |
| 0.007 | 0.057 | 0.044 | VLA-4 antagonist | 0.044 0.014 DBMET01141 | DBMET01141 | |
| 0.015 | 0.067 | 0.024 | ICAM 1 antagonist | 0.024 0.013 DBMET01141 | DBMET01141 | |
| 0.02 | 0.079 | 0.032 | Growth factor receptor-bound protein 2 antagonist | 0.032 0.031 DBMET02776 | DBMET02776 | |
| 0.129 | 0.189 | 0.359 | Tumour necrosis factor alpha release inhibitor | 0.292 0.056 DBMET02775 0.359 0.036 DBMET02776 | DBMET02776 | |
| 0.034 | 0.103 | 0.111 | NMDA 2 receptor antagonist | 0.106 0.029 DBMET01141 0.111 0.027 DBMET02776 | DBMET02776 | |
| 0.09 | 0.161 | 0.134 | Acetylcholine M1 receptor antagonist | 0.119 0.11 DBMET02775 0.134 0.091 DBMET02776 | DBMET02776 | |
| 0.023 | 0.098 | 0.071 | AMPA 4 receptor antagonist | 0.071 0.008 DBMET01141 | DBMET01141 | |
| 0.117 | 0.193 | 0.159 | Antiamyloidogenic | 0.159 0.136 DBMET01141 | DBMET01141 | |
| 0.022 | 0.103 | 0.069 | NMDA receptor subunit 3B antagonist | 0.069 0.016 DBMET01141 | DBMET01141 | |
| 0.07 | 0.153 | 0.115 | Cholinergic antagonist | 0.115 0.079 DBMET02775 0.112 0.081 DBMET02776 | DBMET02775 | |
| 0.018 | 0.102 | 0.048 | Glycine transporter 2 inhibitor | 0.048 0.032 DBMET01141 | DBMET01141 | |
| 0.016 | 0.101 | 0.059 | Nicotinic receptor beta4 subunit antagonist | 0.052 0.015 DBMET02775 0.059 0.012 DBMET02776 | DBMET02776 | |
| 0.024 | 0.111 | 0.061 | GHS receptor agonist | 0.052 0.018 DBMET02775 0.061 0.013 DBMET02776 | DBMET02776 | |
| 0.019 | 0.108 | 0.041 | Growth hormone release inhibitor | 0.041 0.03 DBMET02776 | DBMET02776 | |
| 0.066 | 0.157 | 0.109 | Acetylcholine antagonist | 0.109 0.081 DBMET02775 0.109 0.081 DBMET02776 | DBMET02776 | |
| 0.008 | 0.101 | 0.02 | Integrin beta5 antagonist | 0.02 0.015 DBMET02776 | DBMET02776 | |
| 0.069 | 0.164 | 0.108 | Glutamate (mGluR7) agonist | 0.108 0.045 DBMET01141 | DBMET01141 | |
| 0.158 | 0.264 | 0.231 | 5 Hydroxytryptamine uptake stimulant | 0.231 0.103 DBMET01141 | DBMET01141 | |
| 0.01 | 0.121 | 0.047 | Complement C5a chemotactic receptor antagonist | 0.037 0.014 DBMET02775 0.047 0.009 DBMET02776 | DBMET02776 | |
| 0.017 | 0.131 | 0.04 | Glutamate (mGluR3) antagonist | 0.04 0.021 DBMET01141 | DBMET01141 | |
| 0.016 | 0.141 | 0.048 | Somatostatin 5 agonist | 0.043 0.016 DBMET02775 0.048 0.013 DBMET02776 | DBMET02776 | |
| 0.023 | 0.154 | 0.044 | Kainate receptor agonist | 0.044 0.023 DBMET01141 | DBMET01141 | |
| 0.091 | 0.226 | 0.207 | Tumour necrosis factor antagonist | 0.207 0.049 DBMET02775 | DBMET02775 | |
| 0.126 | 0.262 | 0.196 | DNA synthesis inhibitor | 0.196 0.129 DBMET02776 | DBMET02776 | |
| 0.031 | 0.173 | 0.051 | Factor III inhibitor | 0.051 0.033 DBMET02776 | DBMET02776 | |
| 0.012 | 0.156 | 0.062 | Oxytocin antagonist | 0.056 0.016 DBMET02775 0.062 0.014 DBMET02776 | DBMET02776 | |
| 0.062 | 0.208 | 0.111 | DOPA decarboxylase inhibitor | 0.111 0.057 DBMET01141 | DBMET01141 | |
| 0.043 | 0.198 | 0.117 | Antineoplastic alkaloid | 0.103 0.045 DBMET02775 0.117 0.039 DBMET02776 | DBMET02776 | |
| 0.048 | 0.204 | 0.125 | Glutamate receptor antagonist | 0.125 0.069 DBMET02776 | DBMET02776 | |
| 0.127 | 0.284 | 0.205 | Nootropic | 0.205 0.151 DBMET02775 0.186 0.177 DBMET02776 | DBMET02775 | |
| 0.007 | 0.182 | 0.058 | Sigma receptor antagonist | 0.058 0.029 DBMET02775 0.044 0.038 DBMET02776 | DBMET02775 | |
| 0.026 | 0.202 | 0.065 | Glutamate decarboxylase inhibitor | 0.065 0.061 DBMET01141 | DBMET01141 | |
| 0.043 | 0.226 | 0.114 | Breast cancer-resistant protein inhibitor | 0.112 0.045 DBMET02775 0.114 0.044 DBMET02776 | DBMET02776 | |
| 0.05 | 0.245 | 0.191 | Nav1.4 sodium channel blocker | 0.145 0.036 DBMET02775 0.191 0.021 DBMET02776 | DBMET02776 | |
| 0.019 | 0.229 | 0.087 | Glutamate receptor agonist | 0.087 0.047 DBMET01141 | DBMET01141 | |
| 0.009 | 0.223 | 0.039 | Guanylate cyclase inhibitor | 0.039 0.034 DBMET02776 | DBMET02776 | |
| 0.004 | 0.222 | 0.068 | Growth hormone secretagogue receptor agonist | 0.062 0.016 DBMET02775 0.068 0.014 DBMET02776 | DBMET02776 | |
| 0.014 | 0.234 | 0.07 | p53 inhibitor | 0.07 0.005 DBMET02775 0.064 0.007 DBMET02776 | DBMET02775 | |
| 0.037 | 0.271 | 0.115 | Alkylator | 0.115 0.073 DBMET02775 | DBMET02775 | |
| 0.007 | 0.256 | 0.036 | 1,3-Beta-glucan synthase inhibitor | 0.034 0.007 DBMET02775 0.036 0.005 DBMET02776 | DBMET02776 | |
| 0.005 | 0.275 | 0.262 | Antidiuretic hormone antagonist | 0.262 0.004 DBMET02775 0.245 0.005 DBMET02776 | DBMET02775 | |
| 0.035 | 0.32 | 0.09 | Triose-phosphate isomerase inhibitor | 0.09 0.06 DBMET02776 | DBMET02776 | |
| 0.042 | 0.335 | 0.209 | Nav1.1 sodium channel blocker | 0.131 0.042 DBMET02775 0.209 0.017 DBMET02776 | DBMET02776 | |
| 0.028 | 0.34 | 0.14 | Prolactin inhibitor | 0.14 0.027 DBMET02776 | DBMET02776 | |
| 0.007 | 0.329 | 0.034 | Vasopressin 2 antagonist | 0.029 0.027 DBMET02775 0.034 0.022 DBMET02776 | DBMET02776 | |
| 0.131 | 0.454 | 0.346 | Antiinflammatory | 0.281 0.233 DBMET02775 0.346 0.175 DBMET02776 | DBMET02776 | |
| 0.035 | 0.367 | 0.147 | Interleukin 1b antagonist | 0.147 0.042 DBMET02776 | DBMET02776 | |
| 0.004 | 0.336 | 0.298 | Vasopressin 1 antagonist | 0.298 0.004 DBMET02775 0.28 0.004 DBMET02776 | DBMET02775 | |
| 0.011 | 0.348 | 0.089 | Purinergic P2 antagonist | 0.088 0.028 DBMET02775 0.089 0.027 DBMET02776 | DBMET02776 | |
| 0.004 | 0.376 | 0.229 | Vasopressin 1A antagonist | 0.229 0.004 DBMET02775 0.223 0.004 DBMET02776 | DBMET02775 | |
| 0.008 | 0.403 | 0.165 | NMDA 2B receptor antagonist | 0.115 0.012 DBMET02775 0.165 0.008 DBMET02776 | DBMET02776 | |
| 0.032 | 0.432 | 0.158 | Cell wall synthesis inhibitor | 0.158 0.058 DBMET02776 | DBMET02776 | |
| 0.018 | 0.44 | 0.051 | CC chemokine receptor 2B antagonist | 0.051 0.03 DBMET02776 | DBMET02776 | |
| 0.066 | 0.493 | 0.333 | Antibacterial | 0.333 0.112 DBMET02776 | DBMET02776 | |
| 0.009 | 0.494 | 0.089 | Phosphodiesterase V inhibitor | 0.089 0.034 DBMET02775 0.073 0.049 DBMET02776 | DBMET02775 | |
| 0.009 | 0.501 | 0.086 | Phosphodiesterase 5A inhibitor | 0.086 0.035 DBMET02775 0.068 0.052 DBMET02776 | DBMET02775 | |
| 0.006 | 0.515 | 0.024 | Phosphodiesterase 6H inhibitor | 0.024 0.017 DBMET02775 0.022 0.02 DBMET02776 | DBMET02775 | |
| 0.006 | 0.515 | 0.024 | Phosphodiesterase 6G inhibitor | 0.024 0.017 DBMET02775 0.022 0.02 DBMET02776 | DBMET02775 | |
| 0.006 | 0.549 | 0.069 | Purinergic P2X antagonist | 0.057 0.026 DBMET02775 0.069 0.018 DBMET02776 | DBMET02776 | |
| 0.015 | 0.566 | 0.057 | Phosphodiesterase 6C inhibitor | 0.057 0.011 DBMET02775 0.056 0.012 DBMET02776 | DBMET02775 | |
| 0.007 | 0.561 | 0.066 | CC chemokine 5 receptor antagonist | 0.066 0.021 DBMET02776 | DBMET02776 | |
| 0.028 | 0.582 | 0.377 | Interleukin 6 antagonist | 0.199 0.041 DBMET02775 0.377 0.009 DBMET02776 | DBMET02776 | |
| 0.005 | 0.563 | 0.038 | Purinergic P2X7 antagonist | 0.031 0.03 DBMET02775 0.038 0.023 DBMET02776 | DBMET02776 | |
| 0.005 | 0.57 | 0.031 | Phosphodiesterase 6B inhibitor | 0.031 0.021 DBMET02775 0.028 0.025 DBMET02776 | DBMET02775 | |
| 0.028 | 0.707 | 0.269 | Interleukin 12 antagonist | 0.138 0.017 DBMET02775 0.269 0.004 DBMET02776 | DBMET02776 | |
| 0.02 | 0.71 | 0.091 | mTOR complex 1 inhibitor | 0.091 0.084 DBMET02776 | DBMET02776 | |
| 0.007 | 0.833 | 0.173 | Phosphodiesterase 11A inhibitor | 0.17 0.007 DBMET02775 0.173 0.006 DBMET02776 | DBMET02776 | |
| 0.007 | 0.833 | 0.173 | Phosphodiesterase XI inhibitor | 0.17 0.007 DBMET02775 0.173 0.006 DBMET02776 | DBMET02776 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |